Stock analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The firm has a market capitalization of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The firm’s fifty day moving average price is $0.14. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a 52 week low of $1.22 and a 52 week high of $8.45.
Nabriva Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 4/29 – 5/3
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Roth IRA Calculator: Calculate Your Potential Returns
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.